
Oncotarget
Trending With Impact: Genes Identified in Endocrine Therapy Resistance
Apr 15, 2022
Researchers explore genes responsible for endocrine therapy resistance in breast cancer, utilizing advanced statistical and computational methods. They identify 34 crucial genes related to resistance and triple negative breast cancer, highlighting the need for better understanding to improve treatments.
07:47
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Endocrine therapy resistance in breast cancer involves a novel group of 34 genes with potential therapeutic implications.
- Dynamic gene expression analysis identified shared genetic mechanisms between endocrine resistant breast cancer and triple negative breast cancer, suggesting new treatment strategies.
Deep dives
Identification of Genes in Endocrine Therapy Resistance
Researchers identified a group of 34 novel genes that play fundamental roles in the development and progression of endocrine resistant breast cancer. These genes were found through a new statistical and computational analysis method that studied the dynamic behavior of gene expression during endocrine resistance development. The study revealed that some of these genes were also differentially expressed in triple negative breast cancer (TNBC), hinting at shared genetic mechanisms between the two subtypes of breast cancer. This discovery opens avenues for potential new therapeutic strategies to combat endocrine therapy resistance in these challenging-to-treat breast cancers.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.